WO2001071355A3 - Igf-i, igfbp-3 and psa in prostate cancer prediction - Google Patents

Igf-i, igfbp-3 and psa in prostate cancer prediction Download PDF

Info

Publication number
WO2001071355A3
WO2001071355A3 PCT/US2001/040355 US0140355W WO0171355A3 WO 2001071355 A3 WO2001071355 A3 WO 2001071355A3 US 0140355 W US0140355 W US 0140355W WO 0171355 A3 WO0171355 A3 WO 0171355A3
Authority
WO
WIPO (PCT)
Prior art keywords
psa
igfbp
igf
prostate cancer
cancer prediction
Prior art date
Application number
PCT/US2001/040355
Other languages
French (fr)
Other versions
WO2001071355A2 (en
Inventor
Christos S Mantzoros
Alicja Wolk
Swen-Olof Andersson
Hans-Olov Adami
Dimitrious Trichopoulos
Original Assignee
Beth Israel Hospital
Karolinskas Innovations Ab
Harvard College
Christos S Mantzoros
Alicja Wolk
Andersson Swen Olof
Adami Hans Olov
Dimitrious Trichopoulos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital, Karolinskas Innovations Ab, Harvard College, Christos S Mantzoros, Alicja Wolk, Andersson Swen Olof, Adami Hans Olov, Dimitrious Trichopoulos filed Critical Beth Israel Hospital
Priority to AU2001250051A priority Critical patent/AU2001250051A1/en
Publication of WO2001071355A2 publication Critical patent/WO2001071355A2/en
Publication of WO2001071355A3 publication Critical patent/WO2001071355A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4745—Insulin-like growth factor binding protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2

Abstract

It was determined that the analytes IGF-I and IGFBP-3 can be used to predict the risk of incurring prostate cancer when PSA levels are within certain ranges. Thus, the levels of PSA must also be determined in order to determine how these analytes impact risk. It was found that, when PSA is ≤ 3 ng/ml, the risks for IGF-I and IGFBP-3 are additive. When PSA is > 10 ng/ml, the level of IGFBP-3 can be used to predict risk.
PCT/US2001/040355 2000-03-23 2001-03-22 Igf-i, igfbp-3 and psa in prostate cancer prediction WO2001071355A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001250051A AU2001250051A1 (en) 2000-03-23 2001-03-22 Use of igf-i, igfbp-3 and psa to predict the risk of prostate cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19167800P 2000-03-23 2000-03-23
US60/191,678 2000-03-23

Publications (2)

Publication Number Publication Date
WO2001071355A2 WO2001071355A2 (en) 2001-09-27
WO2001071355A3 true WO2001071355A3 (en) 2002-03-14

Family

ID=22706473

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/040355 WO2001071355A2 (en) 2000-03-23 2001-03-22 Igf-i, igfbp-3 and psa in prostate cancer prediction

Country Status (2)

Country Link
AU (1) AU2001250051A1 (en)
WO (1) WO2001071355A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006074430A2 (en) * 2005-01-07 2006-07-13 The Johins Hopkins University Biomarkers for melanoma
GB0503741D0 (en) * 2005-02-23 2005-03-30 Eden Research Plc Assay
SE536352C2 (en) 2011-10-24 2013-09-03 Chundsell Medicals Ab Cursor genes for classification of prostate cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038011A1 (en) * 1998-01-21 1999-07-29 The Brigham And Women's Hospital, Inc. Circulating insulin-like growth factor-i and prostate cancer risk

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038011A1 (en) * 1998-01-21 1999-07-29 The Brigham And Women's Hospital, Inc. Circulating insulin-like growth factor-i and prostate cancer risk

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHAN J M ET AL: "PLASMA INSULIN-LIKE GROWTH FACTOR-I AND PROSTATE CANCER RISK: A PROSPECTIVE STUDY", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 279, no. 5350, 1998, pages 563 - 566, XP000915424, ISSN: 0036-8075 *
GIOVANNUCCI EDWARD: "Insulin-like growth factor-I and binding protein-3 and risk of cancer.", HORMONE RESEARCH (BASEL), vol. 51, no. Suppl. 3, November 1999 (1999-11-01), The Tenth hGH Symposium;Seville, Spain; April 23-24, 1999, pages 34 - 41, XP001034920, ISSN: 0301-0163 *
GRIMBERG A ET AL: "Growth hormone and prostate cancer: Guilty by association?", JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, vol. 22, no. 5 SUPPL., 1999, pages 64 - 73, XP001034924, ISSN: 0391-4097 *
WOLK ALICJA ET AL: "Can measurements of IGF-1 and IGFBP-3 improve the sensitivity of prostate-cancer screening?", LANCET (NORTH AMERICAN EDITION), vol. 356, no. 9245, 2000, pages 1902 - 1903, XP002184508, ISSN: 0099-5355 *

Also Published As

Publication number Publication date
WO2001071355A2 (en) 2001-09-27
AU2001250051A1 (en) 2001-10-03

Similar Documents

Publication Publication Date Title
AU2001236731A1 (en) Transurethral volume reduction of the prostate (tuvor)
MXPA01006099A (en) Methods and compositions for reducing the permeabilities of subterranean zones.
IL152918A0 (en) Stabilized tetrazolium-phenazine reagent compositions and methods for using the same
AU2003264068A1 (en) Compositions and methods for treating cancer using maytansinoid cd44 antibody immonoconjugates and chemotherapeutic agents
GB2397971A8 (en) Method for routing electronic correspondance based on the level and type of emotion contained therein
GB0409480D0 (en) Fine particle containing rare earth element and fluorescent probe using the same
HK1082242A1 (en) Rare earth metal compounds, methods of making, and methods of using the same
IL150970A0 (en) Devices for analyte concentration determination and methods of using the same
WO2003021940A3 (en) Implementation of mandatory segments in multimedia content
GB0126990D0 (en) Method and composition for improving fuel consumption
EP0959897A4 (en) Method of regulating nitric oxide production
Wilkinson et al. State-of-the-art staging in prostate cancer.
WO2001075178A3 (en) Methods for identifying peptide aptamers capable of altering a cell phenotype
WO2002044360A3 (en) Modified arginine deiminase
AU2001262555A1 (en) Compositions and processes for treating subterranean formations
NZ512487A (en) Iron-containing protein composition
WO2001071355A3 (en) Igf-i, igfbp-3 and psa in prostate cancer prediction
GB0120213D0 (en) On-line transactional display with multiple data type entry facility
IL151264A0 (en) Devices for analyte concentration determination and methods of using the same
WO2003087051A3 (en) Methods for identifying allosteric sites
WO2002020823A3 (en) Methods and compositions for visualizing and interfering with chromosomal tethering of extrachromosomal molecules
IL142386A0 (en) Method for retarding corrosion of metals in lithium halide solutions
AU5830201A (en) Detection of disseminated tumor cells by quantitative rt-pcr of cytokeratin 20 mrna
GB0513178D0 (en) Fine particles containing rare earth element and fluorescent probe using the same
WO2002092012A3 (en) Compositions and methods for treating tumors bearing hmfg and cea antigens

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP